Intracranial Arterial Diseases Market

Market Overview:

The 7 major intracranial arterial diseases markets are expected to exhibit a CAGR of 3.92% during 2024-2034.

The intracranial arterial diseases market has been comprehensively analyzed in IMARC's new report titled "Intracranial Arterial Diseases Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Intracranial arterial diseases refer to a group of conditions that primarily affect the arteries inside the brain. These ailments involve the narrowing, blockage, or weakening of the blood vessels that deliver nutrients and oxygen to the brain. The general symptoms commonly associated with the illnesses include frequent or severe headaches, changes in vision, vertigo, dizziness, mood swings, depression, irritability, memory problems, difficulty concentrating, alterations in thinking abilities, confusion, weakness, paralysis, trouble with speech or language, etc. In some cases, these conditions can lead to seizures, manifesting as uncontrolled movements, convulsions, or altered consciousness. The diagnosis of intracranial arterial diseases typically requires a combination of the patient’s clinical features, medical history, and neurological examination. Numerous imaging techniques, like magnetic resonance angiography, computed tomography scans, digital subtraction angiography, etc., are recommended to visualize the bloodstreams in the brain and detect abnormalities. The healthcare provider may further perform an electroencephalogram (EEG) to evaluate electrical impulses in the central nervous system for diagnosing conditions that may cause seizures or various other irregular brain activities.

The increasing cases of atherosclerosis, which can lead to narrowing or complete blockage of the arteries due to the deposit of fatty substances called plaques within the blood vessels, are primarily driving the intracranial arterial diseases market. In addition to this, the rising incidences of various associated risk factors, such as genetic predisposition, high blood pressure, smoking, certain connective tissue disorders, etc., are also creating a positive outlook for the market. Moreover, the widespread adoption of radiosurgery, that uses highly focused radiation beams to target and treat vascular malformations without the need for open surgery, is further bolstering the market growth. Apart from this, the inflating application of intravenous thrombolysis procedures, since they involve administering a clot-dissolving medication called tissue plasminogen activator (tPA) to restore blood supply to the brain and improve treatment outcomes in patients, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of embolization devices, which can help to divert the blood flow away from the weakened vessel wall, thereby promoting its healing, is expected to drive the intracranial arterial diseases market during the forecast period. 

IMARC Group's new report provides an exhaustive analysis of the intracranial arterial diseases market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for intracranial arterial diseases and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the intracranial arterial diseases market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the intracranial arterial diseases market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the intracranial arterial diseases market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current intracranial arterial diseases marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the intracranial arterial diseases market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the intracranial arterial diseases market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the intracranial arterial diseases market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of intracranial arterial diseases across the seven major markets?
• What is the number of prevalent cases (2018-2034) of intracranial arterial diseases by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of intracranial arterial diseases by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with intracranial arterial diseases across the seven major markets?
• What is the size of the intracranial arterial diseases patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of intracranial arterial diseases?
• What will be the growth rate of patients across the seven major markets?
   

Intracranial Arterial Diseases: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for intracranial arterial diseases drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the intracranial arterial diseases market?
• What are the key regulatory events related to the intracranial arterial diseases market?
• What is the structure of clinical trial landscape by status related to the intracranial arterial diseases market?
• What is the structure of clinical trial landscape by phase related to the intracranial arterial diseases market?
• What is the structure of clinical trial landscape by route of administration related to the intracranial arterial diseases market?